Literature DB >> 21346750

OCT-1 as a determinant of response to antileukemic treatment.

J R Engler1, T P Hughes, D L White.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21346750     DOI： 10.1038/clpt.2011.12

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  4 in total

Review 1.  Contribution of tumoral and host solute carriers to clinical drug response.

Authors:  Jason A Sprowl; Torben S Mikkelsen; Hugh Giovinazzo; Alex Sparreboom
Journal:  Drug Resist Updat       Date:  2012-03-28       Impact factor: 18.500

2.  Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.

Authors:  Luciene Terezina de Lima; Douglas Vivona; Carolina Tosin Bueno; Rosario D C Hirata; Mario H Hirata; André D Luchessi; Fabíola Attié de Castro; Maria de Lourdes F Chauffaille; Maria A Zanichelli; Carlos S Chiattone; Vania T M Hungria; Elvira M Guerra-Shinohara
Journal:  Med Oncol       Date:  2014-01-29       Impact factor: 3.064

3.  Imatinib Affects the Expression of SLC22A1 in a Non-Linear Concentration-Dependent Manner Within 24 Hours.

Authors:  Sandhya Sreenivasan Tantuan; Christopher D Viljoen
Journal:  Med Sci Monit Basic Res       Date:  2018-03-23

4.  Interactions of ABCG2 (BCRP) with epidermal growth factor receptor kinase inhibitors developed for molecular imaging.

Authors:  Israa Qawasmi; Miriam Shmuel; Sara Eyal
Journal:  Front Pharmacol       Date:  2014-11-21       Impact factor: 5.810
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.